pseudouridylic acid
Description
pseudouridylic acid: minor descriptor (72-82); online & Index Medicus search URACIL NUCLEOTIDES (72-82) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
pseudouridine 5'-phosphate : A C-nucleoside phosphate consisting of pseudouridine having a monophosphate group at the 5'-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 439424 |
| CHEBI ID | 18116 |
| SCHEMBL ID | 851399 |
| MeSH ID | M0262463 |
Synonyms (22)
| Synonym |
|---|
| 2,4(1h,3h)-pyrimidinedione, 5-(5-o-phosphono-beta-d-ribofuranosyl)- |
| (1s)-1,4-anhydro-1-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-d-ribitol 5-(dihydrogen phosphate) |
| CHEBI:18116 |
| (1s)-1,4-anhydro-1-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-5-o-phosphono-d-ribitol |
| 5-(5-o-phosphono-beta-d-ribofuranosyl)pyrimidine-2,4(1h,3h)-dione |
| pseudouridylic acid |
| 1157-60-4 |
| pseudouridine 5'-phosphate |
| C01168 |
| pseudouridine-5'-monophosphate |
| DB03829 |
| [(2r,3s,4r,5s)-5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| psu , |
| SCHEMBL851399 |
| {[(2r,3s,4r,5s)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}phosphonic acid |
| Q27102833 |
| [5-(2,4-dioxo-1h-pyrimidin-5-yl)-3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid |
| ((2r,3s,4r,5s)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate |
| 88NC65Q5EZ |
| pseudouridine monophosphate |
| uracil, 5-beta-d-ribofuranosyl-, 5'-(dihydrogen phosphate) |
| 5-(5-o-phosphono-beta-d-ribofuranosyl)-2,4(1h,3h)-pyrimidinedione |
Drug Classes (1)
| Class | Description |
|---|---|
| C-nucleoside phosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Pathways (5)
| Pathway | Proteins | Compounds |
|---|---|---|
| Metabolism | 1496 | 1108 |
| Nucleotide metabolism | 89 | 125 |
| Nucleotide salvage | 21 | 28 |
| Pyrimidine salvage | 9 | 13 |
| Purine Degradation | 2 | 8 |
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 17.29
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (17.29) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||